Vaccines for multiple sclerosis: Progress to date

CNS Drugs

Volumn 22, Issue 3, 2008, Pages 175-198

  Correale, Jorge ^a   Farez, Mauricio ^a   Gilmore, Wendy ^b  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Multiple sclerosis vaccine, therapeutic use; Multiple sclerosis, treatment; Research and development; T cell replacement therapy, therapeutic use

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; FAS LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PLACEBO; PLASMID DNA; PROTEOLIPID PROTEIN; T CELL RECEPTOR PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE VACCINE; TIPLIMOTIDE; TRIPLE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SUBSTITUTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DISEASE COURSE; DISEASE EXACERBATION; DNA IMMUNIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOLECULAR RECOGNITION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REPORTER GENE; REVIEW; SKELETAL MUSCLE; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ANIMALS; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; VACCINATION; VACCINES; VACCINES, DNA;

EID: 39349098254     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822030-00001     Document Type: Review

References (164)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996 Apr; 46 (4): 907-11
2. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747
3. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999 Jun; 12 (3): 309-21
4. Marcos MA, Toribio ML, de la Hera A, et al. Mutual cell interactions and the selection of immune repertoires: implication in autoimmunity. Immunol Today 1988 Jul-Aug; 9 (7-8): 204-7
5. Sospedra M, Martin R. Molecular mimicry in multiple sclerosis. Autoimmunity 2006 Feb; 39 (1): 3-8
6. Wucherpfening KW. Mechanisms for induction of autoimmunity by infectious agents. J Clin Invest 2001 Oct 15; 108 (8): 1097-104
7. Wen L, Wong FS. How can the innate immune system influence autoimmunity in type 1 diabetes and other autoimmune disorders? Crit Rev Immunol 2005; 25 (3): 225-50
8. Li L, Boussiotis VA. Physiologic regulation of central and peripheral tolerance: lessons for therapeutic applications. J Mol Med 2006 Nov; 84 (11): 887-99
9. Goodnow CC, Sprent J, Fazekas de St Groth b, et al. Cellular and genetic mechanisms of self-tolerance and autoimmunity. Nature 2005 Jun 2; 435 (7042): 590-7
10. Tourtellotte WW, Walsh MJ, Baumhefner RW, et al. The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis. Ann N Y Acad Sci 1984; 436: 52-67
11. Link H, Baig S, Jiang YP, et al. B cells antibodies in MS. Res Immunol 1989; 140 (2): 219-26
12. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders: III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977 Sep; 37 (5): 397-401
13. Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labelling, and avidinbiotin amplification. Clin Chem 1984 Jul; 30 (7): 1246-9
14. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994 Aug; 57 (8): 897-902
15. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006 Nov; 180 (1-2): 17-28
16. Correale J, Bassani Molinas M. Oligoclonal bands and antibodies responses in multiple sclerosis. J Neurol 2002 Apr; 249 (4): 375-89
17. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol 2006 Nov; 180 (1-2): 3-8
18. Klawiter EC, Cross AH. B cells: no longer the nondominant arm of multiple sclerosis. Curr Neurol Neeurosci Rep 2007 May; 7 (3): 231-8
19. Charcot JM. Histologie de le sclerose en plaques. Gaz Hop 1868; 41: 554-66
20. Trapp BD, Peterson J, Ransoohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 Jan 29; 338 (5): 278-85
21. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999 Jun; 12 (3): 295-302
22. Cohen JA, Rudick RA, editors. Multiple sclerosis therapeutics. 2nd ed. London: Martin Dunitz Ltd, 2003
23. Burns J, Rosenzweig A, Zweiman B, et al. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983 Oct; 81 (2): 435-40
24. Correale J, McMillan M, McCarthy K, et al. Isolation and characterization of autoreactive proteolipid protein-peptide specific T cell-clones from multiple sclerosis patients. Neurology 1995 Jul; 45 (7): 1370-8
25. Diaz-Villoslada P, Shih A, Shao L, et al. Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. J Neuroimmunol 1999 Sep; 99 (1): 36-43
26. Ben-Nun A, Wekerle H, Cohen I. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981 Jul 2; 292: 60-1
27. Cohen I. Physiological basis of T-cell vaccination against autoimmune disease. Cold Spring Harb Symp Quant Biol 1989; 54 (Pt 2): 879-84
28. Lider O, Reshef T, Beraud E, et al. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988 Jan 8; 239: 181-3
29. Lider O, Karin N, Shinitzky M, et al. Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure. Proc Natl Acad Sci U S A 1987 Jul; 84: 4577-80
30. Beraud E. T cell vaccination in autoimmune diseases. Ann N Y Acad Sci 1991 Dec 30; 636: 124-34
31. Holoshitz J, Naparstek Y, Ben-Nun A, et al. Lines of T lymphocytes induce or vaccinate against autoimmune artritis. Science 1983 Jan 7; 219: 56-8
32. Maron R, Zerubavel R, Friedman A, et al. T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol 1983 Nov; 131 (5): 2316-22
33. Elias D, Reshef T, Birk OS, et al. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDA heat shock protein. Proc Natl Acad Sci U S A 1991 Apr 15; 88 (8): 3088-91
34. Lider O, Beraud E, Reshef T, et al. Vaccination against experimental autoimmune encephalomyelitis using a subencepahlitogenic dose of autoimmune effector T cells: (II). Induction of a protective anti-idiotypic response. J Autoimmun 1989 Feb; 2 (1): 87-99
35. Cohen IR. Natural Id-anti-Id networks and the immunological homunculus. In: Atlan H, Cohen IR, editors. Theories of immune networks. Berlin: Springer-Verlag, 1989: 6-12
36. Zhang J, Vandevyver C, Stinissen P, et al. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. J Immunol 1995 Dec 15; 155 (12): 5868-77
37. Zhang J, Medaer R, Stinissen P, et al. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993 Sep 10; 261: 1451-4
38. Correale J, Lund B, McMillan M, et al. T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 2000 Jul; 107 (2): 130-9
39. Zang YC, Hong J, Rivera VM, et al. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 2000 Apr 15; 164 (8): 4011-7
40. Hong J, Zang YC, Nie H, et al. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 2006 Mar 28; 103 (13): 5024-9
41. Zang YC, Hong J, Tejada-Simon MV, et al. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000 Mar; 30 (3): 908-13
42. Cohen IR. Regulation of autoimmune disease physiological and therapeutic. Immunol Rev 1986 Dec; 94: 5-21
43. Naparstek Y, Ben-Nun A, Holoshitz J, et al. T lymphocyte lines producing or vaccinating against autoimmune encephalomyelitis (EAE): functional activation induces peanut agglutinin receptors and accumulation in the brain and thymus of line cells. Eur J Immunol 1983 May; 13 (5): 418-23
44. Lohse AW, Mor F, Karin N, et al. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 1989 May 19; 244: 820-2
45. Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol 2006 Sep; 64 (3): 205-10
46. Hermans G, Denzer U, Lohse A, et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun 1999 Sep; 13 (2): 233-46
47. Herkel J, Brunner S, Meyer zum Büschenfelde KH, et al. Humoral mechanisms in T cell vaccination: induction and functional characterization of anti-lymphocytic autoantibodies. J Autoimmun 1997 Apr; 10 (2): 137-46
48. Hong J, Zang YC, Tejada-Simon MV, et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol 2000 Dec 15; 165 (12): 6858-64
49. Buenafe AC, Tsaknaridis L, Spencer L, et al. Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 2004 Apr 1; 76 (1): 129-40
50. Haas JA, Hug A, Viehöver B, et al. Reduced suppressive effect of CD4+CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte protein in patients with multiple sclerosis. Eur J Immunol 2005 Nov; 35 (11): 3343-52
51. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 Apr 5; 199 (7): 971-9
52. Kumar M, Putzki N, Limmroth V, et al. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006 Nov; 180 (1-2): 178-84
53. Hermans G, Denzer U, Lohse A, et al. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun 1999 Sep; 13 (2): 233-46
54. Stinissen P, Zhang J, Vandevyver C, et al. Gammadelta T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination. J Neuroimmunol 1998 Jul; 87 (1-2): 94-104
55. Hafler DA, Cohen IR, Benjamin DS, et al. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol 1992 Mar; 62 (3): 307-13
56. Medaer R, Stinissen P, Truyen L, et al. Depletion of myelin-basic-protein autoreactive T cells by T cell vaccination: pilot trial in multiple sclerosis. Lancet 1995 Sep 23; 346: 807-8
57. Zhang JZ, Rivera VM, Tejada-Simon MV, et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002 Feb; 249 (2): 212-8
58. Van der Aa A, Hellings N, Medaer R, et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003 Jan; 131 (1): 155-68
59. Achiron A, Lavie G, Kishner I, et al. T cell vaccination in multiple sclerosis relapsing-remitting non responders patients. Clin Immunol 2004 Nov; 113 (2): 155-60
60. National MS Society. Clinical trials in MS 2007: planned, in progress, recently completed [online]. Available from URL: http://www.nationalmssociety. org/docs/HOM/clinical trials.pdf [Accessed 2008 Jan 28]
61. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33 (11): 1444-52
62. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation and neurodegeneration. Neuron 2006 Oct 5; 52 (1): 61-76
63. Burns FR, Li XB, Shen N, et al. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V alpha and V beta chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989 Jan 1; 169 (1): 27-39
64. Heber-Katz E, Acha-Orbea H. The V-region hypothesis: evidence for autoimmune encephalomyelitis. Immunol Today 1989 May; 10 (5): 164-9
65. Zaller DM, Osman G, Kanagawa O, et al. Prevention and treatment of murine experimental allergic encephalomyelitis with T cell receptor V beta-specific antibodies. J Exp Med 1990 Jun 1; 171 (6): 1943-55
66. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosc Res 1996 Feb 15; 43 (4): 391-402
67. Brostoff SW, Howell MD. Immunoregulation of autoimmune disease by vaccination with T cell receptor peptides. Ann N Y Acad Sci 1991 Dec 30; 636: 71-8
68. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989 Oct 12; 341: 541-4
69. Howell MD, Winster ST, Olee T, et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 1989 Nov 3; 246: 668-70
70. Hashim GA, Vandenbark AA, Galang AB, et al. Antibodies specific for VB8 receptor peptide suppress experimental autoimmune encephalomyelitis. J Immunol 1990 Jun 15; 144 (12): 4621-7
71. Offner H, Adlard K, Bebo Jr BF, et al. Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J Immunol 1998 Sep 1; 161 (5): 2178-86
72. Matejuk A, Vandenbark AA, Burrows GG, et al. Reduced chemokine and chemokine receptor expression in spinal cord of TCR BV8S2 transgenic mice protected against experimental autoimmune encephalomyelitis with BV8S2 protein. J Immunol 2000 Apr 1; 164 (7): 3924-31
73. Bourdette DN, Whitham RH, Chou YK, et al. Immunity to TCR peptides in multiple sclerosis: I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J Immunol 1994 Mar 1; 152 (5): 2510-9
74. Chou YK, Morrison WJ, Weinberg AD, et al. Immunity to TCR peptides in multiple sclerosis: II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994 Mar 1; 152 (5): 2520-9
75. Vandenbark AA, Chou YK, Whitham R, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996 Oct; 2 (10): 1109-15
76. Wilson DB, Golding AB, Smith RA, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis: I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol 1997 Jun; 76 (1-2): 15-28
77. Gold DP, Smith RA, Golding AB, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis: II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR Vβ6 CDR2 peptide. J Neuroimmunol 1997 Jun; 76 (1-2): 29-38
78. Hong J, Zang Y, Tejada-Simoón MV, et al. A common T cell receptor V-D-J séquense in Vβ 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 1999 Sep 15; 163 (6): 3530-8
79. Vandenbark AA, Culberston NE, Bartholomew, et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008; 123 (1): 66-78
80. Ben-Nun A, Liblau RS, Cohen L, et al. Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals. Proc Natl Acad Sci U S A 1991 Mar 15; 88 (6): 2466-70
81. Richert JR, Robinsosn ED, Camphausen K, et al. Diversity of T cell receptor V alpha, V beta and CDR3 expression by myelin basic protein-specific human T-cell clones. Neurology 1995 Oct; 45 (10): 1919-22
82. Hafler DA, Saadeh MG, Kuchroo VK, et al. TCR usage in human and experimental demyelinating disease. Immunol Today 1996 Apr; 17 (4): 152-9
83. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997 May; 120 (5): 865-916
84. Zipp F, Kerschensteiner M, Dornmair K, et al. Diversity of the anti-T cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain 1998 Aug; 121 (8): 1395-407
85. Vandenbark AA, Morgan E, Bartholomew R, et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001 Jun; 26 (6): 713-30
86. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990 Mar 23; 247: 1465-8
87. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993 Mar 19; 59: 1745-9
88. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-74
89. Liu MA, Wahren B, Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006 Nov; 17 (11): 1051-61
90. Urbanek-Ruiz I, Ruiz PJ, Paragas V, et al. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 2001 Aug; 100 (2): 164-71
91. Quintana FJ, Carmi P, Mor F, et al. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. J Immunol. 2003 Oct 1; 171 (7): 3533-41
92. Waisman A, Ruiz PJ, Hirschberg DL, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med 1996 Aug; 2 (8): 899-905
93. Ledwith BJ, Manam S, Troilo PJ, et al. Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol 2000; 104: 33-43
94. Tsunoda I, Kuang LQ, Tolley ND, et al. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J Neuropathol Exp Neurol 1998 Aug; 57 (8): 758-67
95. Nagaraju K. Immunological capabilities of skeletal muscle cells. Acta Physiol Scand 2001 Mar; 171 (3): 215-23
96. Liu MA. DNA vaccines: a review. J Intern Med 2003 Apr; 253 (4): 402-10
97. Kumar V, Maglione J, Thatte J, et al. Induction of a type 1 regulatory CD4 T cell response following V beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int Immunol 2001 Jun; 13 (6): 835-41
98. Braciak TA, Pedersen B, Chin J, et al. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the V beta 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10. J Immunol 2003 Jan 15; 170 (2): 765-74
99. Kumar V, Sercarz E. Induction or protection from experimental autoimmune encepahlomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells. J Immunol 1998 Dec 15; 161 (12): 6585-91
100. Barnett LA, Whitton JL, Wada Y, et al. Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol 1993 Apr; 44 (1): 15-25
101. Barnett LA, Whitton JL, Wang LY, et al. Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. J Neuroimmunol 1996 Feb; 64 (2): 163-73
102. Chunduru SK, Sutherland RM, Stewart GA, et al. Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. J Immunol 1996 Jun 15; 156 (12): 4940-5
103. Wang LY, Fujinami RS. Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol 1997 May; 75 (1-2): 75-83
104. Genain CP, Gritz L, Joshi N, et al. Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for myelin basic protein. J Neuroimmunol 1997 Nov; 79 (2): 119-28
105. Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J Autoimmun 1999 Aug; 13 (1): 21-9
106. Lobell A, Weissert R, Storch MK, et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J Exp Med 1998 May 4; 187 (9): 1543-8
107. Wang LY, Theil DJ, Whitton JL, et al. Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis. J Neuroimmunol 1999 May; 96 (2): 148-57
108. Ruiz PJ, Garren H, Ruiz IU, et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol 1999 Mar 15; 162 (6): 3336-41
109. Lobell A, Weissert R, Eltayeb S, et al. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J Immunol 1999 Nov 1; 163 (9): 4754-62
110. Wildbaum G, Westermann J, Maor G, et al. A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 2000 Sep; 106 (5): 671-9
111. Selmaj K, Kowal C, Walczak A, et al. Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J Neuroimmunol 2000 Nov 1; 111 (1-2): 34-44
112. Bourquin C, Iglesias A, Berger T, et al. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur J Immunol 2000 Dec; 30 (12): 3663-71
113. Garren H, Ruiz PJ, Watkins TA, et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001 Jul; 15 (1): 15-22
114. Lobell A, Weissert R, Eltayeb S, et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J Immunol 2003 Feb 15; 170 (4): 1806-13
115. Wefer J, Harris RA, Lobell A. Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFN beta. J Neuroimmunol 2004 Apr; 149 (1-2): 66-76
116. Walczak A, Szymanska B, Selmaj K. Differential prevention of experimental autoimmune encephalomyelitis with antigen-specific DNA vaccination. Clin Neurol Neurosurg 2004 Jun; 106 (3): 241-5
117. Robinson WH, Fontoura P, Lee BJ, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003 Sep; 21 (9): 1033-9
118. Mueller AM, Pedre X, Kleiter I, et al. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2005 Feb; 159 (1-2): 55-65
119. Ho PP, Fontoura P, Platten M, et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005 Nov 1; 175 (9): 6226-34
120. Schif-Zuck S, Wildbaum G, Karin N. Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system. J Immunol 2006 Dec 1; 177 (11): 8241-7
121. Boccaccio GL, Mor F, Steinman L. Non-coding plasmid DNA induces IFN-gamma in vivo and suppress autoimmune encephalomyelitis. Int Immunol 1999 Feb; 11 (2): 289-96
122. Wildbaum G, Netzer N, Karin N. Plasmid DNA encoding IFN-gamma-inducible protein 10 redirects antigen-specific T cell polarization and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002 Jun 1; 168 (1): 5885-92
123. Donnelly JJ, Wahren B, Lio MA. DNA vaccines progress and challenges. J Immunol 2005 Jul 15; 175 (2): 633-9
124. Lowe DB, Shearer MH, Kennedy RC. DNA vaccines:successes and limitations in cancer and infectious diseases. J Cell Biochem 2006 May 15; 98 (2): 235-42
125. Ota K, Matsui M, Milford EL, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990 Jul 12; 346: 183-7
126. Allen PM, Matsueda GR, Evans RJ, et al. Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature 1987 Jun; 327: 713-5
127. Racioppi L, Ronchese F, Matis LA, et al. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med 1993 Apr 1; 177 (4): 1047-60
128. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14: 1-27
129. Nicholson LB, Greer JM, Sobel RA, et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995 Oct; 3 (4): 397-405
130. Gaur A, Boehme SA, Chalmers D, et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J Neuroimmunol 1997 Apr; 74 (1-2): 149-58
131. Kumar V, Urban JL, Horvath SJ, et al. Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 1990 Feb; 87 (4): 1337-41
132. Franco A, Southwood S, Arrhenius T, et al. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 1994 Apr; 24 (4): 940-6
133. Kuchroo VK, Greer JM, Kaul D, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994 Oct 1; 153 (7): 3326-36
134. Young DA, Lowe LD, Booth SS, et al. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 2000 Apr 1; 164 (7): 3563-72
135. Alleva DG, Gaur A, Jin L, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand NBI-6024, based on the immunodominant type 1 diabetes autologous insulin- B chain (9-23) peptide. Diabetes 2002 Jul; 51 (7): 2126-34
136. Crowe PD, Boehme SA, Wong T, et al. Differential signaling and hierarchical response thresholds induced by an immunodominant peptide of myelin basic protein and an altered peptide ligand in human T cells. Hum Immunol 1998 Nov; 59 (11): 679-89
137. Madrenas J, Wange RL, Wang JL, et al. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 1995 Jan 27; 267: 515-8
138. Santambrogio L, Lees MB, Sobel RA. Altered peptide ligand modulation of experimental allergic encephalomyelitis: immune responses within the CNS. J Neuroimmunol 1998 Jan; 81 (1-2): 1-13
139. Crowe PD. Qin Y, Conlon PJ, et al. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol 2000 Nov; 48 (5): 758-65
140. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 Oct; 6 (10): 1167-75
141. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000 Oct; 6 (10): 1176-82
142. Kim HJ, Antel JP, Duquette P, et al. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002 Aug; 104 (2): 105-14
143. Sandvig A, Berry M, Barrett LB, et al. Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression receptor signalling, and correlation with axon regeneration. Glia 2004 May; 46 (3): 225-51
144. Karnezis T, Mandemakers W, McQualter JL, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004 Jul; 7 (7): 736-44
145. Xu G, Nie DY, Chen JT, et al. Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration. J Neurochem 2004 Nov; 91 (4): 1018-23
146. Fontoura P, Ho PP, DeVoss J, et al. Immunity to extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol 2004 Dec 1; 173 (11): 6981-92
147. Link H, Huang YM, Masterman T, et al. Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis. J Neuroimmunol 2001 Mar; 114 (1-2): 1-7
148. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 Mar 19; 392: 245-52
149. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity. Trends Immunol 2002 Sep; 23 (9): 445-9
150. Legge KL, Gregg RK, Maldonado-Lopez R, et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med 2002 Jul 15; 196 (2): 217-27
151. Shinomiya M, Fazle Akbar SM, Shinomiya H, et al. Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 1999 Jul; 117 (1): 38-43
152. Xiao BG, Wu XC, Yang JS, et al. Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 2004 Jan; 16 (1): 13-22
153. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997 Nov 15; 159 (10): 4772-80
154. Bartholome EJ, Willems F, Crusiaux A, et al. Interferon-beta inhibits Th1 responses at the dendritic cell level: relevance to multiple sclerosis. Acta Neurol Belg 1999 Mar; 99 (1): 44-52
155. Iruretagoyena MI, Sepúlveda SE, Lezana JP, et al. Inhibition of nuclear factor-κB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 2006 Jul; 318 (1): 59-67
156. Xiao BG, Huang YM, Yang JS, et al. Bone marrow-derived dendritic cells from experimental allergic encephalomyelitis induce immune tolerance to EAE in Lewis rat. Clin Exp Immunol 2001 Aug; 125 (2): 300-9
157. Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000 Apr 15; 95 (8): 2484-90
158. Menges M, Rossner S, Voigtlander C, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002 Jan; 195 (1): 15-21
159. Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002 Aug 19; 20 (25-26): 3104-12
160. Chakerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001 Aug; 108 (3): 415-23
161. Röhn TA, Jennings GT, Hernandez M, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006 Nov; 36 (11): 2857-67
162. Uyttenhove C, Sommereyens C, Théate I, et al. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 2007; 1110: 330-6
163. Uyttenhove C, Arendse B, Stroobant V, et al. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 2004 Dec; 34 (12): 3572-81
164. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007; 64 (10): 1407-15